Medindia

X

Patent Approval for Products of Living Cell Technologies and HealthLinx

by Savitha C Muppala on  February 24, 2011 at 6:37 PM Corporate News   - G J E 4
Encapsulation technology, IMMUPEL, by Living Cell Technologies (ASX:LCT) has received an Australian patent , while HealthLinx (ASX:HTX) has received a UK patent for its OvPlex diagnostic technology.
 Patent Approval for Products of Living Cell Technologies and HealthLinx
Patent Approval for Products of Living Cell Technologies and HealthLinx
Advertisement

IMMUPEL holds the technology for encapsulation of living cells, which can be transplanted into patients. Since the encapsulated cells are protected from the immune system, there is no need for immunosuppressant drugs. An example of this technology is LCT's DIABECELL, which encapsulates porcine insulin-producing cells, that are later injected into patients with Type 1 diabetes.

Advertisement
HealthLinx (ASX:HTX), the Melbourne-based company has also received patent approval for its OvPlex diagnostic product from the UK patent office. The product basically searches for biomarkers in a sample of blood to detect the presence of ovarian cancer.  



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All